FDA Issues Guidance In Quest For First Drug To Prevent Inhalational Anthrax

FDA, following a multi-year effort, on Wednesday (May 23) released final guidance aimed at spurring development of drugs to prevent inhalational anthrax in individuals who potentially could be exposed to or have inhaled aerosolized anthrax spores but haven't yet shown symptoms of the disease. The guidance clarifies that development of such drugs can rely on animal studies, since it would be unethical to deliberately expose healthy human volunteers to B. anthracis spores. The agency has already approved drugs to treat...